High estrogen and chronic haloperidol lead to greater amphetamine-induced BOLD activation in awake, amphetamine-sensitized female rats

Hormones and Behavior

Volumn 82, Issue , 2016, Pages 56-63

  Madularu, Dan ^a   Kulkarni, Praveen ^b   Yee, Jason R ^b   Kenkel, William M ^b   Shams, Waqqas M ^a   Ferris, Craig F ^b   Brake, Wayne G ^a  

^a Center for Studies in Behavioural Neurobiology ^*  (Canada)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Antipsychotic; Dopamine; Estradiol; FMRI; Ovariectomy; Schizophrenia

Indexed keywords

AMPHETAMINE; ESTRADIOL; HALOPERIDOL; DOPAMINE; NEUROLEPTIC AGENT; OXYGEN;

AMYGDALA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLD SIGNAL; BRAIN FUNCTION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG SENSITIZATION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HABENULA; HIPPOCAMPUS; HORMONE ACTION; HORMONE SUBSTITUTION; HYPOTHALAMUS; NERVE CELL NETWORK; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RADIOLOGICAL PARAMETERS; RAT; SCHIZOPHRENIA; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; WAKEFULNESS;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; ESTRADIOL; FEMALE; HALOPERIDOL; MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; WAKEFULNESS;

EID: 84966713297     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2016.04.007     Document Type: Article

References (65)

1. Akhondzadeh S., Nejatisafa A.A., Amini H., Mohammadi M.R., Larijani B., Kashani L., Raisi F., Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27:1007-1012.
2. Almey A., Filardo E.J., Milner T.A., Brake W.G. Estrogen receptors are found in glia and at extranuclear neuronal sites in the dorsal striatum of female rats: evidence for cholinergic but not dopaminergic colocalization. Endocrinology 2012, 153:5373-5383.
3. Almey A., Hafez N.M., Hantson A., Brake W.G. Deficits in latent inhibition induced by estradiol replacement are ameliorated by haloperidol treatment. Front. Behav. Neurosci. 2013, 7:136.
4. Antelman S.M., Kocan D., Edwards D.J., Knopf S., Perel J.M., Stiller R. Behavioral effects of a single neuroleptic treatment grow with the passage of time. Brain Res. 1986, 385:58-67.
5. Antelman S.M., Caggiula A.R., Kocan D., Knopf S., Meyer D., Edwards D.J., Barry H. One experience with 'lower' or 'higher' intensity stressors, respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability. Brain Res. 1991, 566:276-283.
6. Antelman S.M., Kocan D., Knopf S., Edwards D.J., Caggiula A.R. One brief exposure to a psychological stressor induces long-lasting, time-dependent sensitization of both the cataleptic and neurochemical responses to haloperidol. Life Sci. 1992, 51:261-266.
7. Bazzett T.J., Becker J.B. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res. 1994, 637:163-172.
8. Becker J.B. Estrogen rapidly potentiates amphetamine-induced striatal dopamine release and rotational behavior during microdialysis. Neurosci. Lett. 1990, 118:169-171.
9. Bosse R., Rivest R., Di Paolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res. Mol. Brain Res. 1997, 46:343-346.
10. Brailoiu E., Dun S.L., Brailoiu G.C., Mizuo K., Sklar L.A., Oprea T.I., Prossnitz E.R., Dun N.J. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J. Endocrinol. 2007, 193:311-321.
11. Brevard M.E., Duong T.Q., King J.A., Ferris C.F. Changes in MRI signal intensity during hypercapnic challenge under conscious and anesthetized conditions. Magn. Reson. Imaging 2003, 21:995-1001.
12. Castle D., Sham P., Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr. Res. 1998, 33:179-183.
13. Charron A., Hage C.E., Servonnet A., Samaha A.N. 5-HT receptors modulate the expression of antipsychotic-induced dopamine supersensitivity. Eur. Neuropsychopharmacol. 2015.
14. Chiodo L.A., Caggiula A.R., Saller C.F. Estrogen increases both spiperone-induced catalepsy and brain levels of [3H]spiperone in the rat. Brain Res. 1979, 172:360-366.
15. De Ryck M., Hruska R.E., Silbergeld E.K. Estrogen and haloperidol-induced versus handling-related catalepsy in male rats. Pharmacol. Biochem. Behav. 1982, 17:1027-1035.
16. El Hage C., Bedard A.M., Samaha A.N. Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function. Neuropharmacology 2015.
17. Euvrard C., Oberlander C., Boissier J.R. Antidopaminergic effect of estrogens at the striatal level. J. Pharmacol. Exp. Ther. 1980, 214:179-185.
18. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:1556-1571.
19. Febo M., Ferris C.F., Segarra A.C. Estrogen influences cocaine-induced blood oxygen level-dependent signal changes in female rats. J. Neurosci. 2005, 25:1132-1136.
20. Ferris C.F., Kulkarni P., Toddes S., Yee J., Kenkel W., Nedelman M. Studies on the Q175 knock-in model of Huntington's disease using functional imaging in awake mice: evidence of olfactory dysfunction. Front. Neurol. 2014, 5:94.
21. Gass N., Schwarz A.J., Sartorius A., Cleppien D., Zheng L., Schenker E., Risterucci C., Meyer-Lindenberg A., Weber-Fahr W. Haloperidol modulates midbrain-prefrontal functional connectivity in the rat brain. Eur. Neuropsychopharmacol. 2013, 23:1310-1319.
22. Genovese C.R., Lazar N.A., Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. NeuroImage 2002, 15:870-878.
23. Grigoriadis S., Seeman M.V. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can. J. Psychiatr. 2002, 47:437-442.
24. Hruska R.E., Silbergeld E.K. Estrogen treatment enhances dopamine receptor sensitivity in the rat striatum. Eur. J. Pharmacol. 1980, 61:397-400.
25. Hruska R.E., Silbergeld E.K. Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science 1980, 208:1466-1468.
26. Hruska R.E., Ludmer L.M., Pitman K.T., De Ryck M., Silbergeld E.K. Effects of estrogen on striatal dopamine receptor function in male and female rats. Pharmacol. Biochem. Behav. 1982, 16:285-291.
27. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157:514-520.
28. King J.A., Garelick T.S., Brevard M.E., Chen W., Messenger T.L., Duong T.Q., Ferris C.F. Procedure for minimizing stress for fMRI studies in conscious rats. J. Neurosci. Methods 2005, 148:154-160.
29. Kulkarni J., de Castella A., Smith D., Taffe J., Keks N., Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 1996, 20:247-252.
30. Kulkarni J., Riedel A., de Castella A.R., Fitzgerald P.B., Rolfe T.J., Taffe J., Burger H. Estrogen - a potential treatment for schizophrenia. Schizophr. Res. 2001, 48:137-144.
31. LeDuc P.A., Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology 1995, 121:407-427.
32. Madularu D., Shams W.M., Brake W.G. Estrogen potentiates the behavioral and nucleus accumbens dopamine response to continuous haloperidol treatment in female rats. Eur. J. Neurosci. 2014, 39:257-265.
33. Madularu D., Kulkarni P., Ferris C.F., Brake W.G. Changes in brain volume in response to estradiol levels, amphetamine sensitization and haloperidol treatment in awake female rats. Brain Res. 2015.
34. Madularu D., Yee J.R., Kenkel W.M., Moore K.A., Kulkarni P., Shams W.M., Ferris C.F., Brake W.G. Integration of neural networks activated by amphetamine in females with different estrogen levels: a functional imaging study in awake rats. Psychoneuroendocrinology 2015, 56:200-212.
35. Mannino C.A., South S.M., Inturrisi C.E., Quinones-Jenab V. Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. J. Pain 2005, 6:809-816.
36. Montague D., Weickert C.S., Tomaskovic-Crook E., Rothmond D.A., Kleinman J.E., Rubinow D.R. Oestrogen receptor alpha localisation in the prefrontal cortex of three mammalian species. J. Neuroendocrinol. 2008, 20:893-903.
37. Osterlund M., Kuiper G.G., Gustafsson J.A., Hurd Y.L. Differential distribution and regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res. Mol. Brain Res. 1998, 54:175-180.
38. Overpeck J.G., Colson S.H., Hohmann J.R., Applestine M.S., Reilly J.F. Concentrations of circulating steroids in normal prepubertal and adult male and female humans, chimpanzees, rhesus monkeys, rats, mice, and hamsters: a literature survey. J. Toxicol. Environ. Health 1978, 4:785-803.
39. Paulson P.E., Robinson T.E. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse 1995, 19:56-65.
40. Paulson P.E., Camp D.M., Robinson T.E. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 1991, 103:480-492.
41. Peleg-Raibstein D., Knuesel I., Feldon J. Amphetamine sensitization in rats as an animal model of schizophrenia. Behav. Brain Res. 2008, 191:190-201.
42. Perez-Neri I., Mendez-Sanchez I., Montes S., Rios C. Acute dehydroepiandrosterone treatment exerts different effects on dopamine and serotonin turnover ratios in the rat corpus striatum and nucleus accumbens. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32:1584-1589.
43. Peris J., Decambre N., Coleman-Hardee M.L., Simpkins J.W. Estradiol enhances behavioral sensitization to cocaine and amphetamine-stimulated striatal [3H]dopamine release. Brain Res. 1991, 566:255-264.
44. Riecher-Rossler A., Hafner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology?. Schizophr. Bull. 1994, 20:203-214.
45. Robinson T.E. Behavioral sensitization: characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats. Psychopharmacology 1984, 84:466-475.
46. Robinson T.E., Becker J.B., Presty S.K. Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences. Brain Res. 1982, 253:231-241.
47. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2:e141.
48. Samaha A.N. Can antipsychotic treatment contribute to drug addiction in schizophrenia?. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 52:9-16.
49. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007, 27:2979-2986.
50. Samaha A.N., Reckless G.E., Seeman P., Diwan M., Nobrega J.N., Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry 2008, 64:145-152.
51. Sanchez M.G., Bourque M., Morissette M., Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 2010, 16:e43-e71.
52. Sanchez M.G., Morissette M., Di Paolo T. Effect of a chronic treatment with 17beta-estradiol on striatal dopamine neurotransmission and the Akt/GSK3 signaling pathway in the brain of ovariectomized monkeys. Psychoneuroendocrinology 2012, 37:280-291.
53. Sarvari M., Deli L., Kocsis P., Mark L., Maasz G., Hrabovszky E., Kallo I., Gajari D., Vastagh C., Sumegi B., Tihanyi K., Liposits Z. Estradiol and isotype-selective estrogen receptor agonists modulate the mesocortical dopaminergic system in gonadectomized female rats. Brain Res. 2014.
54. Schmidt W.J., Beninger R.J. Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia. Neurotox. Res. 2006, 10:161-166.
55. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry 1998, 3:123-134.
56. Shughrue P.J., Merchenthaler I. Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system. J. Comp. Neurol. 2001, 436:64-81.
57. Spary E.J., Chapman S.E., Sinfield J.K., Maqbool A., Kaye J., Batten T.F. Novel G protein-coupled oestrogen receptor GPR30 shows changes in mRNA expression in the rat brain over the oestrous cycle. Neurosignals 2013, 21:14-27.
58. Tenn C.C., Fletcher P.J., Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr. Res. 2003, 64:103-114.
59. Van Hest A., van Haaren F., van de Poll N.E. Haloperidol, but not apomorphine, differentially affects low response rates of male and female Wistar rats. Pharmacol. Biochem. Behav. 1988, 29:529-532.
60. Vernon A.C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry 2011, 69:936-944.
61. Vernon A.C., Natesan S., Crum W.R., Cooper J.D., Modo M., Williams S.C., Kapur S. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol. Psychiatry 2012, 71:855-863.
62. Vernon A.C., Crum W.R., Lerch J.P., Chege W., Natesan S., Modo M., Cooper J.D., Williams S.C., Kapur S. Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology. Biol. Psychiatry 2014, 75:982-990.
63. Vezina P. D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. J. Neurosci. 1996, 16:2411-2420.
64. Xue C.J., Ng J.P., Li Y., Wolf M.E. Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. J. Neurochem. 1996, 67:352-363.
65. Zhang K., Tarazi F.I., Campbell A., Baldessarini R.J. GABA(B) receptors: altered coupling to G-proteins in rats sensitized to amphetamine. Neuroscience 2000, 101:5-10.